Urology treats urinary tract diseases in all genders and male reproductive issues, covering the kidneys, bladder, prostate, urethra, from infections to complex cancers.
Send us all your questions or requests, and our expert team will assist you.
The foundational step in treatment is Radical Inguinal Orchiectomy. This procedure involves removing the affected testicle and spermatic cord through an incision in the groin (inguinal canal), rather than the scrotum. This approach respects the embryological lymphatic drainage planes, preventing aberrant spread of tumor cells. Surgical precision is paramount to ensure the cord is ligated high at the internal inguinal ring, removing all potential lymphatic channels that could harbor cancer cells.
For patients with small, non-palpable masses or benign findings, testis-sparing surgery (partial orchiectomy) may be considered. This requires intraoperative ultrasound guidance and frozen section analysis to ensure negative margins. This approach preserves hormonal function and fertility but is reserved for carefully selected cases in specialized centers.
For non-seminomatous tumors with residual masses or high risk of recurrence, Retroperitoneal Lymph Node Dissection (RPLND) is performed. This complex surgery involves removing the lymphatic tissue around the aorta and vena cava. The modern standard is the “nerve-sparing” RPLND. The sympathetic nerve fibers responsible for seminal emission run alongside these vessels. Damage to these nerves results in retrograde ejaculation (dry orgasm).
Robotic-assisted RPLND has emerged as a minimally invasive alternative to open surgery. The robotic platform provides magnified 3D visualization and dexterity, enabling surgeons to meticulously dissect lymph nodes while preserving delicate postganglionic sympathetic nerve fibers. This significantly reduces blood loss, hospital stay, and recovery time, while maintaining oncological equivalence to open surgery in experienced hands.
Chemotherapy is the cornerstone of treatment for metastatic disease. The standard regimen is BEP (Bleomycin, Etoposide, Cisplatin). Cisplatin is a platinum-based agent that cross-links DNA, triggering apoptosis in rapidly dividing germ cells. This regimen is remarkably effective, curing the vast majority of patients. However, the cellular toxicity is systemic.
Bleomycin can cause pulmonary fibrosis by generating free radicals in the lung tissue. Cisplatin is nephrotoxic and ototoxic (damaging hearing). Etoposide carries a small risk of secondary leukemia. Modern care protocols involve strict monitoring of lung and kidney function. Biotechnological advancements are exploring targeted therapies that might replace these cytotoxic agents in cases of resistance, reducing systemic collateral damage. High-dose chemotherapy with autologous stem cell transplant is utilized for relapsed disease, leveraging the principles of bone marrow regeneration to support aggressive treatment.
Radiotherapy is primarily used for seminomas, which are exquisitely sensitive to ionizing radiation. The energy beams damage tumor cells’ DNA, preventing replication. Modern techniques like Intensity Modulated Radiation Therapy (IMRT) allow for the precise shaping of the radiation field to match the lymph nodes, sparing surrounding organs like the kidneys and bowel. Proton beam therapy is also being investigated to reduce the exit dose of radiation further, minimizing long-term risks of secondary malignancies in young survivors.
Preserving reproductive potential is a critical component of care. Sperm banking (cryopreservation) is offered before any chemotherapy, radiation, or RPLND. Chemotherapy targets rapidly dividing cells, and the spermatogonial stem cells are highly susceptible. While spermatogenesis often recovers, there is a risk of permanent azoospermia.
For patients with bilateral cancer or those requiring bilateral orchiectomy, testosterone replacement therapy is initiated to maintain physiological function. Research into testicular tissue banking for prepubertal boys is an active area of regenerative medicine, with the goal of re-implanting stem cells later in life to restore natural fertility.
Liv Hospital Ulus
Prof. MD. Engin Kaya
Urology
Liv Hospital Ulus
Prof. MD. Orhan Tanrıverdi
Urology
Liv Hospital Ulus
Prof. MD. Tahir Karadeniz
Urology
Liv Hospital Ulus
Prof. MD. Uğur Boylu
Urology
Liv Hospital Vadistanbul
Assoc. Prof. MD. Eymen Gazel
Urology
Liv Hospital Vadistanbul
Op. MD. Kenan Yiğit Yıldız
Urology
Liv Hospital Vadistanbul
Op. MD. Miraç Turan
Urology
Liv Hospital Vadistanbul
Prof. MD. Selçuk Şahin
Urology
Liv Hospital Vadistanbul
Prof. MD. Volkan Tuğcu
Urology
Liv Hospital Vadistanbul
Prof. MD. Yusuf Oğuz Acar
Urology
Liv Hospital Vadistanbul
Spec. MD. Anar Mammadov
Urology
Liv Hospital Bahçeşehir
Op. MD. Fırat Akdeniz
Urology
Liv Hospital Bahçeşehir
Prof. MD. Ayhan Karaköse
Urology
Liv Hospital Topkapı
Op. MD. Birgi Ercili
Urology
Liv Hospital Topkapı
Spec. MD. Timuçin Çakır
Urology
Liv Hospital Ankara
Asst. Prof. MD. Ahmet Yıldız
Urology
Liv Hospital Ankara
Prof. MD. Ziya Akbulut
Urology
Liv Hospital Ankara
Prof. MD. Çağrı Güneri
Urology
Liv Hospital Gaziantep
Op. MD. Kazım Doğan
Urology
Liv Hospital Gaziantep
Prof. MD. Faruk Küçükdurmaz
Urology
Liv Hospital Samsun
Op. MD. Çağlar Yıldırım
Urology
Liv Hospital Samsun
Op. Md. İdris Kıvanç Cavıldak
Urology
Prof. MD. Kadir Önem
Urology
Send us all your questions or requests, and our expert team will assist you.
Robotic RPLND uses small incisions and high-definition cameras. This allows the surgeon to see the nerves and blood vessels much better than in open surgery. Patients typically have less pain, less blood loss, a shorter hospital stay (often 1-2 days versus 5-7 days), and a faster return to normal activities, with similar cancer cure rates.
Chemotherapy attacks rapidly dividing cells, including sperm producing cells. While many men recover sperm production 1 to 2 years after treatment, there is a risk of permanent infertility, especially with higher doses or certain drugs. This is why sperm banking before starting treatment is strongly recommended for all patients.
For stage I cancer (confined to the testicle), the risk of recurrence after surgery is relatively low (15-30%, depending on type). Instead of giving everyone chemotherapy or radiation (which would overtreat the majority), doctors closely monitor the patient with CT scans and blood tests. Treatment is started only if the cancer comes back. This spares many men from side effects.
Usually, no. A single healthy testicle produces enough testosterone and sperm to maintain normal masculinity, libido, sexual function, and fertility. The remaining testicle often undergoes compensatory growth. However, if the remaining testicle is small or unhealthy, testosterone replacement may be needed.
A testicular prosthesis is a saline-filled silicone implant placed in the scrotum to mimic the look and feel of a natural testicle. It can be inserted at the time of cancer surgery or later. It serves a cosmetic and psychological purpose, helping to restore body image and confidence after orchiectomy.
BlogTesticular CancerDec 29, 2025Nearly 9,500 new cases of testicular cancer are diagnosed each year in the United States. This highlights t...
BlogTesticular CancerDec 29, 2025Testicular cancer often hits young men, making it a big concern. Knowing the symptoms early is key to treat...
BlogTesticular CancerDec 29, 2025Testicular cancer is rare but treatable, mainly affecting young men. One in every 250 men will develop test...
BlogTesticular CancerDec 29, 2025The rate of testicular cancer has gone up in recent years in places like the U.S. and Europe. This has led ...
BlogTesticular CancerDec 29, 2025Did you know that testicular cancer has one of the highest cure rates among all types of cancer? Recent stu...
BlogTesticular CancerDec 29, 2025Testicular cancer is rare but common in men aged 15-35. One in 250 men will be diagnosed with testicular ca...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 510 67 91